Literature DB >> 18250304

Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia.

Su-Jiang Zhang1, Li-Yuan Ma, Qiu-Hua Huang, Guo Li, Bai-Wei Gu, Xiao-Dong Gao, Jing-Yi Shi, Yue-Ying Wang, Li Gao, Xun Cai, Rui-Bao Ren, Jiang Zhu, Zhu Chen, Sai-Juan Chen.   

Abstract

Acquisition of additional genetic and/or epigenetic abnormalities other than the BCR/ABL fusion gene is believed to cause disease progression in chronic myeloid leukemia (CML) from chronic phase to blast crisis (BC). To gain insights into the underlying mechanisms of progression to BC, we screened DNA samples from CML patients during blast transformation for mutations in a number of transcription factor genes that are critical for myeloid-lymphoid development. In 85 cases of CML blast transformation, we identified two new mutations in the coding region of GATA-2, a negative regulator of hematopoietic stem/progenitor cell differentiation. A L359V substitution within zinc finger domain (ZF) 2 of GATA-2 was found in eight cases with myelomonoblastic features, whereas an in-frame deletion of 6 aa (delta341-346) spanning the C-terminal border of ZF1 was detected in one patient at myeloid BC with eosinophilia. Further studies indicated that L359V not only increased transactivation activity of GATA-2 but also enhanced its inhibitory effects on the activity of PU.1, a major regulator of myelopoiesis. Consistent with the myelomonoblastic features of CML transformation with the GATA-2 L359V mutant, transduction of the GATA-2 L359V mutant into HL-60 cells or BCR/ABL-harboring murine cells disturbed myelomonocytic differentiation/proliferation in vitro and in vivo, respectively. These data strongly suggest that GATA-2 mutations may play a role in acute myeloid transformation in a subset of CML patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250304      PMCID: PMC2538883          DOI: 10.1073/pnas.0711824105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription.

Authors:  C Nerlov; E Querfurth; H Kulessa; T Graf
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

Review 2.  Focus on acute leukemias.

Authors:  D Gary Gilliland; Martin S Tallman
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

3.  Levels of GATA-1/GATA-2 transcription factors modulate expression of embryonic and fetal hemoglobins.

Authors:  P Ikonomi; C T Noguchi; W Miller; H Kassahun; R Hardison; A N Schechter
Journal:  Gene       Date:  2000-12-31       Impact factor: 3.688

4.  BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

Authors:  Danilo Perrotti; Vincenzo Cesi; Rossana Trotta; Clara Guerzoni; Giorgia Santilli; Kenneth Campbell; Angela Iervolino; Fabrizio Condorelli; Carlo Gambacorti-Passerini; Michael A Caligiuri; Bruno Calabretta
Journal:  Nat Genet       Date:  2001-12-20       Impact factor: 38.330

Review 5.  New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

Authors:  Hagop M Kantarjian; Moshe Talpaz; Francis Giles; Susan O'Brien; Jorge Cortes
Journal:  Ann Intern Med       Date:  2006-12-19       Impact factor: 25.391

6.  Mutations of the transcription factor AML1/CBFA2 are uncommon in blastic transformation of chronic myeloid leukaemia.

Authors:  E J Steer; J M Goldman; N C Cross
Journal:  Leukemia       Date:  2001-03       Impact factor: 11.528

7.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.

Authors:  T Pabst; B U Mueller; P Zhang; H S Radomska; S Narravula; S Schnittger; G Behre; W Hiddemann; D G Tenen
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

8.  A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.

Authors:  Ajeeta B Dash; Ifor R Williams; Jeffery L Kutok; Michael H Tomasson; Ema Anastasiadou; Kathleen Lindahl; Shaoguang Li; Richard A Van Etten; Julian Borrow; David Housman; Brian Druker; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

9.  Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.

Authors:  G M Cuenco; R Ren
Journal:  Oncogene       Date:  2001-12-13       Impact factor: 9.867

10.  BCR-ABL down-regulates the DNA repair protein DNA-PKcs.

Authors:  E Deutsch; A Dugray; B AbdulKarim; E Marangoni; L Maggiorella; S Vaganay; R M'Kacher; S D Rasy; F Eschwege; W Vainchenker; A G Turhan; J Bourhis
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

View more
  82 in total

1.  GATA2 mutations lead to MDS and AML.

Authors:  R Katherine Hyde; P Paul Liu
Journal:  Nat Genet       Date:  2011-09-28       Impact factor: 38.330

2.  Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells.

Authors:  Angelina Felici; Alessio Giubellino; Donald P Bottaro
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

Review 3.  Pituitary gland development and disease: from stem cell to hormone production.

Authors:  Shannon W Davis; Buffy S Ellsworth; María Inés Peréz Millan; Peter Gergics; Vanessa Schade; Nastaran Foyouzi; Michelle L Brinkmeier; Amanda H Mortensen; Sally A Camper
Journal:  Curr Top Dev Biol       Date:  2013       Impact factor: 4.897

Review 4.  Polycomb group proteins: navigators of lineage pathways led astray in cancer.

Authors:  Adrian P Bracken; Kristian Helin
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

Review 5.  Genetic events other than BCR-ABL1.

Authors:  Paolo Neviani
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

6.  GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies.

Authors:  Xinan Wang; Hideki Muramatsu; Yusuke Okuno; Hirotoshi Sakaguchi; Kenichi Yoshida; Nozomu Kawashima; Yinyan Xu; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Shoji Saito; Yozo Nakazawa; Taro Masunari; Tadashi Hirose; Shaimaa Elmahdi; Atsushi Narita; Sayoko Doisaki; Olfat Ismael; Hideki Makishima; Asahito Hama; Satoru Miyano; Yoshiyuki Takahashi; Seishi Ogawa; Seiji Kojima
Journal:  Haematologica       Date:  2015-05-28       Impact factor: 9.941

7.  Characterisation of a compound in-cis GATA2 germline mutation in a pedigree presenting with myelodysplastic syndrome/acute myeloid leukemia with concurrent thrombocytopenia.

Authors:  C N Hahn; P J Brautigan; C-E Chong; A Janssan; P Venugopal; Y Lee; A E Tims; M S Horwitz; M Klingler-Hoffmann; H S Scott
Journal:  Leukemia       Date:  2015-02-13       Impact factor: 11.528

8.  High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Authors:  Marlène Pasquet; Christine Bellanné-Chantelot; Suzanne Tavitian; Naïs Prade; Blandine Beaupain; Olivier Larochelle; Arnaud Petit; Pierre Rohrlich; Christophe Ferrand; Eric Van Den Neste; Hélène A Poirel; Thierry Lamy; Marie Ouachée-Chardin; Véronique Mansat-De Mas; Jill Corre; Christian Récher; Geneviève Plat; Françoise Bachelerie; Jean Donadieu; Eric Delabesse
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 9.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

10.  Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer.

Authors:  Lei Chen; Beihai Jiang; Zaozao Wang; Maoxing Liu; Yiyuan Ma; Hong Yang; Jiadi Xing; Chenghai Zhang; Zhendan Yao; Nan Zhang; Ming Cui; Xiangqian Su
Journal:  Med Oncol       Date:  2013-02-20       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.